HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benzethonium Chloride Bioavailability, Toxicity Studies Planned By Lonza

This article was originally published in The Rose Sheet

Executive Summary

The safety of benzethonium chloride in differing vehicles will be tested through a combination of in vitro dermal penetration studies and a toxicokinetic study in rats to be conducted by Lonza, Inc.

You may also be interested in...



Benzethonium Chloride Review Urged By Lonza Before Final Monograph

FDA should complete a safety review of benzethonium chloride as a Category I active ingredient for the healthcare antiseptic products monograph before finalizing the rule, chemical ingredient supplier Lonza says in a recent letter to the agency.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel